 RANCHO CUCAMONGA, Calif., May 07, 2021 GLOBE NEWSWIRE -- Amphastar Pharmaceuticals, Inc. NASDAQ: AMPH announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. ANP. As part of the restructuring, Amphastar will buyback 26 of ANPs equity currently held by third parties. In addition, ANP will spin-off its Chinese subsidiary, Nanjing Hanxin Pharmaceutical Technology Co., Ltd. and Hanxins subsidiaries collectively, Hanxin. The restructuring is subject to regulatory approval, and the total cash payment by Amphastar for this restructuring will be approximately 29 million. 